Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has been assigned an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $71.80.
A number of research analysts recently issued reports on BHVN shares. ValuEngine downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, June 19th. Morgan Stanley set a $50.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Goldman Sachs Group started coverage on shares of Biohaven Pharmaceutical in a research note on Monday, May 6th. They issued a “buy” rating and a $92.00 price target for the company. Oppenheimer set a $68.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, June 19th. Finally, Piper Jaffray Companies lifted their price target on shares of Biohaven Pharmaceutical from $75.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th.
In other Biohaven Pharmaceutical news, Director John W. Childs bought 10,000 shares of the business’s stock in a transaction dated Wednesday, June 26th. The shares were acquired at an average cost of $40.37 per share, with a total value of $403,700.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO James Engelhart bought 2,500 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was acquired at an average cost of $43.05 per share, for a total transaction of $107,625.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 17,500 shares of company stock worth $712,425. 23.90% of the stock is owned by corporate insiders.
Shares of Biohaven Pharmaceutical stock opened at $38.83 on Friday. Biohaven Pharmaceutical has a 52-week low of $29.17 and a 52-week high of $67.86. The business has a 50 day moving average price of $42.69. The stock has a market capitalization of $1.74 billion, a P/E ratio of -6.31 and a beta of 0.24.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.26). As a group, sell-side analysts predict that Biohaven Pharmaceutical will post -6.26 EPS for the current fiscal year.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Featured Article: Should you buy a closed-end mutual fund?
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.